Business Context and Reporting Period
Company: Anika Therapeutics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2009
Business Overview: Anika develops, manufactures, and commercializes therapeutic products based on hyaluronic acid (HA) for tissue protection, healing, and repair. Key product lines include joint health (ORTHOVISC, MONOVISC), ophthalmic viscoelastics (AMVISC), veterinary products (HYVISC), and aesthetic dermatology (HYDRELLE/ELEVESS). The company operates as a single reportable segment with all operations located in the United States.
Key Financial Metrics
| Metric (Nine Months Ended Sep 30, 2009) | Value |
|---|---|
| Total Revenue | $29,516,764 |
| Net Income | $2,990,419 |
| Diluted EPS | $0.26 |
| Product Gross Margin | 63.3% |
| Cash and Cash Equivalents | $38,540,295 |
| Working Capital | $45,882,102 |
| Total Debt Outstanding | $14,800,000 |
| Net Cash Used in Operating Activities | ($73,034) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 10.1% year-over-year (YoY) for the nine months ended September 30, 2009, compared to $26.8 million in 2008. Product revenue rose 10.5% to $27.4 million.
- Profitability: Net income increased 18.0% to $2.99 million. Operating income grew 33.8% to $3.98 million.
- Product Mix Shifts:
- Joint Health: Revenue increased 24.3% YoY, driven by strong performance of ORTHOVISC in the U.S. and international expansion.
- Aesthetics: Revenue surged 90.7% YoY, primarily due to the commencement of U.S. sales to new distributor Coapt Systems, Inc. in Q3 2009.
- Ophthalmic: Revenue decreased 5.5% YoY, attributed to order timing and inventory management by partners (primarily Bausch & Lomb).
- Veterinary: Revenue declined 24.5% YoY due to inventory management by partner Boehringer Ingelheim Vetmedica.
- Expense Increases: Research & Development (R&D) expenses rose 38.5% to $6.86 million, driven by clinical trials for MONOVISC and facility validation. Selling, General & Administrative (SG&A) expenses increased slightly by 1.1%.
- Cash Flow: Operating cash flow turned negative ($73k used) compared to a positive $2.22 million in the prior year, largely due to increased working capital needs (inventory and accounts receivable buildup).
Guidance, Outlook, and Risks
- Outlook: Management expects joint health product revenue to increase in 2009 compared to 2008. R&D spending is expected to increase at a slower rate in the future. Capital expenditures are expected to decrease in 2010 as the new Bedford, MA facility project winds down.
- Facility Expansion: The company is transitioning manufacturing to a new facility in Bedford, MA. Validation is expected to be completed in 2010, with manufacturing expected to begin in late 2009. Approximately $1 million remains to be spent on the project.
- Regulatory Risks:
- FDA Warning Letter: The company received a Warning Letter in July 2008 regarding its Woburn facility. While the FDA indicated responses were sufficient in September 2008, follow-up inspections are ongoing. Failure to resolve these issues could materially adversely affect operations.
- MONOVISC Approval: The company expects to file a Premarket Approval (PMA) application with the FDA for MONOVISC before the end of 2009.
- Legal Contingencies: An ongoing trademark opposition by Colbar Lifescience Ltd. (a J&J subsidiary) regarding the "ELEVESS" trademark remains unresolved. The company does not believe this will result in impairment of the intangible asset ($892,157 carrying value) but notes the outcome could impact future recoverability.
- Liquidity: Management believes existing cash ($38.5 million) and future cash flows are sufficient to meet requirements for the foreseeable future. The company has a $14.8 million term loan with Bank of America.
Investor Verification Checklist
- Facility Transition: Verify the timeline and regulatory clearance for the new Bedford manufacturing facility, as delays could impact production capacity.
- MONOVISC PMA: Monitor the status of the PMA filing and FDA review for the single-injection osteoarthritis product MONOVISC.
- Customer Concentration: Note that DePuy Mitek (J&J) and Bausch & Lomb represent significant portions of product revenue (44.4% and 27.0% respectively for the nine months ended Sep 30, 2009).
- Trademark Litigation: Track the resolution of the ELEVESS trademark opposition, which could affect international branding and asset valuation.
- Working Capital Trends: Monitor the trend of negative operating cash flow caused by inventory and receivable buildups to ensure liquidity remains adequate.